Medication info
Pigli 15 mg (Pioglitazone Hydrochloride)

Pigli 15 mg (Pioglitazone Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Pioglitazone Hydrochloride›16.53mg / 1 tablet
Manufacturer / importer
Youngil Pharmaceutical Co., Ltd.
Appearance
White to grayish-white, convex, cylindrical tablets
Packaging
30 tablets/bottle, 100 tablets/bottle
Approval status
Active

MFDS item code 200704284 · Approved 2007.04.12 · Insurance code 649402830

Summary

Main use
Improvement of glycemic control in type 2 diabetes
Who takes it
Adults · Children
Adult dose
This medicine is administered orally once daily, regardless of meals. Diabetes management should be individualized for each patient. The ideal approach is to evaluate the response to treatment by monitoring glycated hemoglobin (HbA1c), which is a more accurate diagnostic measure than fasting blood glucose (FBG). Glycated hemoglobin reflects blood glucose levels over the past 2 ~ 3 months. Clinically, this medicine should be administered for an appropriate period (at least 3 months) to assess changes in glycated hemoglobin, provided that glycemic control in the patient with diabetes does not worsen. 1. Monotherapy This medicine may be initiated as monotherapy at 15 mg of pioglitazone once daily in patients whose blood glucose is not adequately controlled with diet and exercise. If an adequate effect is not achieved with the initial dose, the dose of this medicine may be increased to 30 mg once daily. Combination therapy should be considered for patients who do not respond adequately to monotherapy. 2. Combination therapy 1) Sulfonylureas: This medicine may be administered in combination with a sulfonylurea; the initial dose is 15 mg once daily. When used in combination with this medicine, the patient's current sulfonylurea may be continued at the same dose and schedule. However, if the patient develops symptoms of hypoglycemia, the sulfonylurea dose should be reduced. 2) Metformin: This medicine may be administered in combination with metformin; the initial dose is 15 mg once daily. When used in combination with this medicine, the patient's current metformin may be continued at the same dose and schedule. It is unlikely that the metformin dose will need to be adjusted because of hypoglycemic symptoms during combination therapy with this medicine. 3) Insulin: This medicine may be administered in combination with insulin at a dose of 15 mg once daily. The patient's current insulin dose may be continued when combination therapy with this medicine is initiated. However, if a patient receiving this medicine in combination with insulin develops symptoms of hypoglycemia or the plasma glucose concentration decreases to 100 mg/dL or below, the insulin dose may be reduced by 10 ~ 25 %. Subsequent dose adjustments should be individualized according to glycemic control. • Maximum recommended dose For monotherapy or combination therapy with a sulfonylurea, metformin, or insulin, doses exceeding 30 mg once daily are not recommended. Dose adjustment is not recommended in patients with renal impairment (see Renal Impairment in General Precautions). Treatment with this medicine should not be initiated if, at the start of treatment, the patient has clinical evidence of active liver disease or elevated serum aminotransferase levels (at least 2.5 times the upper limit of normal for ALT) (see Effects on the Liver under Adverse Reactions and General Precautions). Monitoring of liver enzymes is recommended in all patients before starting treatment with this medicine and periodically thereafter. There are no data on use of this medicine in combination with other thiazolidinediones.
Child dose
Children under 18 years of age: Use is not recommended because there is no experience with its use.

Ingredients

Manufacturer
Youngil Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes

  • Blood sugar control issues in patients with type 2 diabetes
View approved original text

This medication is used as an adjunct to diet and exercise to help control blood sugar levels in patients with type 2 diabetes. It can be administered alone or combined with sulfonylureas, metformin, or insulin if there is insufficient improvement in blood sugar levels after using other oral hypoglycemic agents. During treatment, nutritional counseling, weight loss, and exercise are also vital, as these contribute not only to initial treatment but also help maintain the effectiveness of medication therapy. This medication is used effectively to improve blood sugar control.

How to take

Adult dose

This medicine is administered orally once daily, regardless of meals. Diabetes management should be individualized for each patient. The ideal approach is to evaluate the response to treatment by monitoring glycated hemoglobin (HbA1c), which is a more accurate diagnostic measure than fasting blood glucose (FBG). Glycated hemoglobin reflects blood glucose levels over the past 2 ~ 3 months. Clinically, this medicine should be administered for an appropriate period (at least 3 months) to assess changes in glycated hemoglobin, provided that glycemic control in the patient with diabetes does not worsen. 1. Monotherapy This medicine may be initiated as monotherapy at 15 mg of pioglitazone once daily in patients whose blood glucose is not adequately controlled with diet and exercise. If an adequate effect is not achieved with the initial dose, the dose of this medicine may be increased to 30 mg once daily. Combination therapy should be considered for patients who do not respond adequately to monotherapy. 2. Combination therapy 1) Sulfonylureas: This medicine may be administered in combination with a sulfonylurea; the initial dose is 15 mg once daily. When used in combination with this medicine, the patient's current sulfonylurea may be continued at the same dose and schedule. However, if the patient develops symptoms of hypoglycemia, the sulfonylurea dose should be reduced. 2) Metformin: This medicine may be administered in combination with metformin; the initial dose is 15 mg once daily. When used in combination with this medicine, the patient's current metformin may be continued at the same dose and schedule. It is unlikely that the metformin dose will need to be adjusted because of hypoglycemic symptoms during combination therapy with this medicine. 3) Insulin: This medicine may be administered in combination with insulin at a dose of 15 mg once daily. The patient's current insulin dose may be continued when combination therapy with this medicine is initiated. However, if a patient receiving this medicine in combination with insulin develops symptoms of hypoglycemia or the plasma glucose concentration decreases to 100 mg/dL or below, the insulin dose may be reduced by 10 ~ 25 %. Subsequent dose adjustments should be individualized according to glycemic control. • Maximum recommended dose For monotherapy or combination therapy with a sulfonylurea, metformin, or insulin, doses exceeding 30 mg once daily are not recommended. Dose adjustment is not recommended in patients with renal impairment (see Renal Impairment in General Precautions). Treatment with this medicine should not be initiated if, at the start of treatment, the patient has clinical evidence of active liver disease or elevated serum aminotransferase levels (at least 2.5 times the upper limit of normal for ALT) (see Effects on the Liver under Adverse Reactions and General Precautions). Monitoring of liver enzymes is recommended in all patients before starting treatment with this medicine and periodically thereafter. There are no data on use of this medicine in combination with other thiazolidinediones.

Child dose

Children under 18 years of age: Use is not recommended because there is no experience with its use.

Precautions

This medication is used for the treatment of diabetes and is effective only when insulin is present to lower blood sugar levels. This medication may worsen heart failure, therefore it should not be used in patients with heart failure or a history of heart failure. During treatment, fluid retention may occur, leading to symptoms such as edema, rapid weight gain, or difficulty breathing, which should be carefully monitored, and any such symptoms should be reported to a physician immediately. Patients with active bladder cancer or a history of bladder cancer should not take this medication. Caution is needed in patients with impaired liver function or severe kidney impairment, and regular liver and kidney function tests should be performed. As this medication poses a risk of hypoglycemia, those taking it with insulin or other hypoglycemic agents should be cautious of hypoglycemic symptoms, and dose adjustments may be necessary for other medications if needed. Side effects such as edema, weight gain, headache, upper respiratory infection may occur, so any of these symptoms should be reported to the attending physician. For premenopausal women, this medication may induce ovulation, increasing the likelihood of pregnancy, thus appropriate contraceptive methods should be used. It is recommended that women who are pregnant or may become pregnant do not take this medication, and that breastfeeding women consult a physician before taking it. This medication has not been studied in children and adolescents under 18 years of age, so its use is not recommended. Elderly patients should also use caution when taking this medication, especially those over 75 years old who should use it more cautiously. During the use of this medication, regular blood sugar and liver function tests should be performed, and any unusual symptoms should be reported to a physician immediately. There may not be specific symptoms associated with overdose, but appropriate treatment should be performed according to clinical symptoms. There may be drug interactions, so patients taking other medications must inform their physician or pharmacist. This medication should be kept out of reach of children and stored in its original container.

Side effects

  • Congestive heart failure
  • excessive and rapid weight changes
  • shortness of breath
  • edema
  • fluid retention
  • heart failure
  • visible hematuria
  • urination disorders
  • urgency
  • upper respiratory infection
Show 55 more
  • headache
  • sinusitis
  • myalgia
  • pharyngitis
  • abdominal distension
  • weight gain
  • hypoglycemia
  • urinary tract infection
  • lumbago
  • dizziness
  • diarrhea
  • elevated serum creatine kinase
  • hypertension
  • heart failure
  • orthostatic hypotension
  • palpitations
  • stroke
  • sexual dysfunction
  • myocardial infarction
  • loss of appetite
  • constipation
  • upper abdominal pain
  • chest pain
  • fatigue
  • weakness
  • dyspepsia
  • nausea
  • shortness of breath
  • itching
  • chest discomfort
  • tremors
  • chills
  • gastrointestinal disease
  • abdominal pain
  • epigastric discomfort
  • numbness
  • muscle stiffness
  • discomfort in the head
  • increased liver enzymes
  • exacerbation of liver disease
  • urticaria
  • eczema
  • arthralgia
  • knee abnormalities
  • arm weakness
  • proteinuria
  • elevated serum creatinine
  • anxiety
  • insomnia
  • drowsiness
  • simple herpes
  • blurred vision
  • lumbago
  • macular edema
  • fracture

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to protect it from air and moisture. Additionally, it should be stored at room temperature between 1 to 30 degrees Celsius, avoiding excessively hot or cold areas.

Appearance and packaging

Appearance

White to grayish-white, convex, cylindrical tablets

Package unit

30 tablets/bottle, 100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.